Abstract
Background: Sentinel Lymph Node Biopsy (SLNB) represents a minimally invasive technique for axillary staging in early breast cancer. SLNB is useful in surgical complications risk reducing compared to complete axillary lymph node dissection (CALND). Micrometastases (MM) prognostic value has been recently challenged. The 2011 St Gallen Consensus Conference recommended that micrometastases in a single sentinel node should not be an indication for axillary dissection irrespective of the type of breast surgery given.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
